Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Revenue $ 3,762 $ 3,891 $ 9,550 $ 15,634
Operating expenses:        
Research and development 28,280 25,759 86,650 84,030
General and administrative 7,764 8,076 22,394 21,970
Transaction related expenses   9,510   9,510
Restructuring (Note 13) 2,354   2,354  
Total operating expenses 38,398 43,345 111,398 115,510
Loss from operations (34,636) (39,454) (101,848) (99,876)
Interest income 1,633 392 5,533 539
Interest expense (1,303) (1,051) (3,798) (3,008)
Change in fair value of warrant liabilities (5,837) 9,860 (77) 12,465
Net loss applicable to common stockholders $ (40,143) $ (30,253) $ (100,190) $ (89,880)
Net loss per share applicable to common stockholders - basic $ (1.43) $ (3.21) $ (3.59) $ (11.93)
Net loss per share applicable to common stockholders - diluted $ (1.43) $ (3.21) $ (3.59) $ (11.93)
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic 27,990,558 9,417,069 27,915,951 7,536,149
Weighted-average number of common shares used in net loss per share applicable to common stockholders - diluted 27,990,558 9,417,069 27,915,951 7,536,149